


Oxyfedrine

Cat. No.:	HY-112070
CAS No.:	15687-41-9
Molecular Formula:	C ₁₉ H ₂₃ NO ₃
Molecular Weight:	313.39
Target:	Adrenergic Receptor
Pathway:	GPCR/G Protein; Neuronal Signaling
Storage:	Please store the product under the recommended conditions in the Certificate of Analysis.



BIOLOGICAL ACTIVITY

Description	Oxyfedrine, a vasodilator, is an orally active β -adrenoreceptor agonist. Oxyfedrine decreases the tonicity of coronary vessels. Oxyfedrine can be used in the research of cardiovascular disease ^{[1][2]} .								
IC₅₀ & Target	β -adrenoceptor								
In Vitro	<p>Oxyfedrine (50 μM, 48 h) suppresses aldehyde dehydrogenase (ALDH) activity in HCT116 and HSC-4 cells^[1].</p> <p>Oxyfedrine (50 μM, 48 h) acts as a sensitizer for GSH-depleting agents, and induces cell death in HCT116 and HSC-4 cells when with the drug combinations^[1].</p> <p>Oxyfedrine (0-1 μg/mL) inhibits spontaneous myogenic activity in rat isolated portal vein^[4].</p> <p>MCE has not independently confirmed the accuracy of these methods. They are for reference only.</p>								
In Vivo	<p>Oxyfedrine (14 mg/kg, p.o., for 3-4 weeks) shows anti-anginal action in cats^[2].</p> <p>Oxyfedrine (10 mg/kg, i.p., HCT116 cell xenograft mice) suppresses tumor growth when combined with sulfasalazine (SSZ, 350 mg/kg, i.p.)^[1].</p> <p>Oxyfedrine (1 mg/kg, i.v.) decreases the arterial and venous blood high blood viscosity (HBV) in ice water stress rats^[3].</p> <p>MCE has not independently confirmed the accuracy of these methods. They are for reference only.</p> <table border="1" style="width: 100%; border-collapse: collapse;"> <tr> <td style="width: 30%;">Animal Model:</td> <td>Cats^[2]</td> </tr> <tr> <td>Dosage:</td> <td>14 mg/kg</td> </tr> <tr> <td>Administration:</td> <td>Oral administration (p.o.), for 3-4 weeks.</td> </tr> <tr> <td>Result:</td> <td>Decreased systolic and diastolic blood pressures, increased heart rate and cardiac output.</td> </tr> </table>	Animal Model:	Cats ^[2]	Dosage:	14 mg/kg	Administration:	Oral administration (p.o.), for 3-4 weeks.	Result:	Decreased systolic and diastolic blood pressures, increased heart rate and cardiac output.
Animal Model:	Cats ^[2]								
Dosage:	14 mg/kg								
Administration:	Oral administration (p.o.), for 3-4 weeks.								
Result:	Decreased systolic and diastolic blood pressures, increased heart rate and cardiac output.								

REFERENCES

- [1]. Otsuki Y, et al. Vasodilator oxyfedrine inhibits aldehyde metabolism and thereby sensitizes cancer cells to xCT-targeted therapy. *Cancer Sci.* 2020 Jan;111(1):127-136.
- [2]. Parratt JR. The haemodynamic effects of prolonged oral administration of oxyfedrine, a partial agonist at beta-adrenoceptors: comparison with propranolol. *Br J Pharmacol.* 1974 May;51(1):5-13.
- [3]. Yu J, et al. [Effects of oxyfedrine on high blood viscosity and myocardial necrosis induced by epinephrine and ice water stress in rats]. *Zhongguo Yao Li Xue Bao.* 1993

Jul;14(4):364-6.

[4]. Mackenzie JE, et al. Effects of oxyfedrine on isolated portal vein and other smooth muscles. Br J Pharmacol. 1973 Apr;47(4):827-37.

Caution: Product has not been fully validated for medical applications. For research use only.

Tel: 609-228-6898

Fax: 609-228-5909

E-mail: tech@MedChemExpress.com

Address: 1 Deer Park Dr, Suite Q, Monmouth Junction, NJ 08852, USA